OC
ATRA icon

Oppenheimer & Co’s Atara Biotherapeutics ATRA Stock Holding History

Oppenheimer & Co’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-666
Closed -$24.6K – 1391
2023
Q3 		$24.6K Sell
666
-237
-26% -$10.5K ﹤0.01% 1362
2023
Q2 		$36.3K Sell
903
-149
-14% -$8.43K ﹤0.01% 1391
2023
Q1 		$76.3K Sell
1,052
-42
-4% -$4.07K ﹤0.01% 1334
2022
Q4 		$89.7K Sell
1,094
-119
-10% -$12.4K ﹤0.01% 1297
2022
Q3 		$115K Sell
1,213
-162
-12% -$18.2K ﹤0.01% 1289
2022
Q2 		$268K Sell
1,375
-66
-5% -$10.8K 0.01% 1147
2022
Q1 		$335K Buy
1,441
+37
+3% +$11.8K 0.01% 1152
2021
Q4 		$553K Buy
1,404
+6
+0.4% +$2.53K 0.01% 997
2021
Q3 		$625K Buy
1,398
+624
+81% +$224K 0.01% 925
2021
Q2 		$301K Buy
774
+23
+3% +$8.2K 0.01% 1238
2021
Q1 		$270K Buy
751
+25
+3% +$11.1K 0.01% 1225
2020
Q4 		$356K Buy
726
+43
+6% +$19.8K 0.01% 1030
2020
Q3 		$221K Buy
+683
New +$233K 0.01% 1118
2019
Q4 		– Sell
-507
Closed -$179K – 1275
2019
Q3 		$179K Buy
507
+102
+25% +$38.1K ﹤0.01% 1162
2019
Q2 		$203K Buy
405
+53
+15% +$37.4K 0.01% 1183
2019
Q1 		$350K Buy
352
+50
+17% +$46.5K 0.01% 966
2018
Q4 		$262K Sell
302
-2
-0.7% -$1.86K 0.01% 1000
2018
Q3 		$315K Hold
304
– – 0.01% 1047
2018
Q2 		$280K Buy
+304
New +$327K 0.01% 1085

Other funds holding ATRA

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Oppenheimer & Co's ATRA Position: Q4 2023 in Review

Oppenheimer & Co sold out of Atara Biotherapeutics (ATRA) in Q4 2023, closing a stake of 666 shares — an estimated $24.6K sold.

Oppenheimer & Co first reported a position in ATRA in Q2 2018 and held it in 19 quarters. The position peaked at $625K in Q3 2021. 90 funds tracked by Wall St. Rank hold ATRA as of Q4 2023.

  • Oppenheimer & Co reported no remaining Atara Biotherapeutics position as of Q4 2023 after selling out during the quarter.
  • Oppenheimer & Co sold 666 Atara Biotherapeutics shares in Q4 2023, an estimated $24.6K.
  • Oppenheimer & Co first reported a position in Atara Biotherapeutics in Q2 2018 and held it in 19 quarters.
  • Oppenheimer & Co's Atara Biotherapeutics position peaked at $625K in Q3 2021.
  • 90 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2023.

Based on Oppenheimer & Co's 13F filing for Q4 2023, filed 13 Feb 2024.